

NORTHEASTERN VERMONT REGIONAL HOSPITAL

FY 2022 BUDGET PRESENTATION to GREEN MOUNTAIN CARE BOARD

AUGUST 19, 2021

GMCB PRESENTATION

- 1. Introduction/Overview/Hospital Vision
- 2. Net Patient Revenue/Fixed Prospective Payments & Summary of Budget Request
- 3. Income statement, balance sheet, and cash flow statement
 - i. NPR/FPP (Medicare, Medicaid, and Commercial Revenue Assumptions)Charge Request
 - ii. Adjustments (provider transfers and/or accounting adjustments)
 - iii. Other Operating and Non-Operating Revenue
 - iv. Operating Expenses
 - v. Operating Margin and Total Margin
- 4. Risks and Opportunities
- 5. Value-Based Care Participation
- 6. Capital Investment Plans
- 7. Other: Impact of COVID-19 on access to care/wait times at your organization, including theuse of telehealth and telemedicine, COVID-19 related safety protocols, and other relevant factors.



INTRODUCTION/OVERVIEW/VISION

Introducing the NVRH Senior Leadership Team

- Shawn Burroughs, MBA CIO, 2017
- Diana Gibbs, MHA VP Community Health Improvement/Marketing, 2021
- Betty Ann Gwatkin, MBA, SHRM-SCP CHRO, 1999
- Bob Hersey, MBA, FHFMA CFO, 1999
- Laura Newell, MSHCA VP Operations & Medical Practices, 2018
- Michael Rousse, MD CMO, 2015
- Julie Schneckenburger, MS, RN, CNOR CNO, 2013
- Colleen Sinon, RN, CPHRM VP Quality Mgmt Programs, 1996
- Shawn Tester, MSOL CEO, 2018



INTRODUCTION/OVERVIEW/VISION

Hospital Overview



Independent, 25-Bed Critical Access Hospital



Service Area = 30,000 Population



Emergency Room Visits = 12,500 Annually



14 Medical Practices: 10 Specialty, 4 Rural Health Clinics



684 Employees


NVRH Vision: – "To Be A Leader in Improving the Health of Our Community"

INTRODUCTION/OVERVIEW/VISION

FY 2022 Budget Overview:

- Budgeted operating margin of \$2,065,000 or 2% of Total Operating Revenue
- Requesting 3.0% average charge increase
- Expanding and adding services to meet community needs
- Continued focus on reducing avoidable Emergency Department visits
- Expanding participation in Value-Based Payment Programs

INTRODUCTORY REMARKS FROM OUR CEO





INCOME STATEMENT, BALANCE SHEET & CASH FLOW INCOME STATEMENT

| INCOME STATEMENT | 2020 A | 2021 B | 2021 PROJ | 2022 B |
|--------------------------------------|---------------|----------------|----------------|----------------|
| Revenues | | | | |
| Gross Patient Care Revenue | \$169,222,081 | \$193,629,600 | \$191,972,700 | \$203,382,600 |
| Disproportionate Share Payments | \$972,598 | \$919,700 | \$1,029,300 | \$926,400 |
| Graduate Medical Education (UVMMC | \$0 | \$0 | \$0 | \$0 |
| Bad Debt | -\$2,570,475 | -\$3,773,400 | -\$2,730,800 | -\$2,879,100 |
| Free Care | -\$2,623,396 | -\$3,014,000 | -\$2,701,500 | -\$2,843,100 |
| Deductions from Revenue | -\$85,929,972 | -\$105,035,600 | -\$101,953,200 | -\$109,757,666 |
| Net Patient Care Revenue | \$79,070,836 | \$82,726,300 | \$85,616,500 | \$88,829,134 |
| Fixed Prospective Payments | \$6,704,919 | \$8,399,000 | \$8,042,064 | \$9,027,154 |
| Reserves | \$0 | -\$600,000 | -\$312,500 | -\$812,500 |
| Other Reform Payments | \$0 | \$0 | \$378,898 | \$325,000 |
| Fixed Prospective Payments and Reser | \$6,704,919 | \$7,799,000 | \$8,108,462 | \$8,539,654 |
| Net Patient Care Rev & Fixed Payment | \$85,775,755 | \$90,525,300 | \$93,724,962 | \$97,368,788 |
| 340B Retail Pharmacy Programs | \$2,712,187 | \$2,575,000 | \$2,314,633 | \$2,400,000 |
| COVID-19 Stimulus and Other Grant | \$1,788,510 | \$597,400 | \$1,160,140 | \$0 |
| Grant Income | \$117,759 | \$0 | \$0 | \$0 |
| Reference Lab Revenue | \$1,458,431 | \$1,525,000 | \$1,731,307 | \$1,725,000 |
| Meaningful Use | \$0 | \$0 | \$0 | \$0 |
| Other | \$34,000 | \$210,000 | \$339,540 | \$340,100 |
| Other Operating Revenue | \$6,110,887 | \$4,907,400 | \$5,545,620 | \$4,465,100 |
| Total Operating Revenue | \$91,886,642 | \$95,432,700 | \$99,270,582 | \$101,833,888 |
| Operating Expenses | | | | |
| Salaries, Fringe Benefits, MD Fees | \$54,305,978 | \$62,771,420 | \$60,057,600 | \$63,799,600 |
| Health Care Provider Tax | \$4,968,780 | \$4,700,000 | \$5,272,800 | \$5,525,000 |
| Depreciation Amortization | \$3,196,677 | \$3,110,000 | \$3,159,700 | \$3,508,500 |
| Interest | \$231,980 | \$200,700 | \$211,100 | \$176,700 |
| ACO Dues | \$157,129 | \$0 | \$150,000 | \$200,000 |
| Other Operating Expenses | \$27,844,880 | \$22,705,880 | \$28,436,126 | \$26,559,050 |
| Total Operating Expenses | \$90,705,424 | \$93,488,000 | \$97,287,326 | \$99,768,850 |
| | | | | |
| Net Operating Income | \$1,181,218 | \$1,944,700 | \$1,983,256 | \$2,065,038 |
| Non Operating Revenue | \$2,418,526 | \$0 | \$3,503,586 | \$0 |
| Excess (Deficit) of Rev over Exp | \$3,599,744 | \$1,944,700 | \$5,486,842 | \$2,065,038 |



INCOME STATEMENT, BALANCE SHEET & CASH FLOW NPR/FPP-FY 2021 BUDGET to FY 2022 BUDGET

Net Patient Revenue Variance Réconciliation FY 2021 Budget to FY 2022 Budget Description % Amount Comments FY 21 Budget Net Patient Revenue \$ 90,525,300 NPR Change Due to Volume 1,571,500 1.7% Returning to pre-COVID Volume Levels Unbudgeted COVID Testing NPR 425,000 0.5% **Ongoing Testing Anticipated** Change in FPP & Other Reform Payments 740,700 0.8% Increased Medicaid Attribution; VBIF Favorable DSH Revenue Change 6,700 0.0% Medicare Sequestration Waiver 143,000 0.2% Waiver to Expire December 31, 2021 Uncompensated Care Change 1,065,200 1.2% Shift from Uncomp Care to Medicaid Enrollment Increase Use Infusion Drug (One Drug) 278,500 0.3% Annual Cost now \$1.1 Million NPR Change New/Expanded Services 1.477.600 1.6% Pulmonology, ENT, Pain Management Change in Payer Mix (48,000)-0.1% Change From Rate Increase 1,203,800 1.3% \$401,300 per 1% Other (20,500)0.0% Projected FY 2021 NPR \$ 97,368,800 7.6% Analysis of NPR Increase **Amount** % Volume Returning to Pre-COVID Levels \$ 1,571,500 1.7% Expanded/New Services 1,477,600 1.6% COVID Testing 425,000 0.5% Infusion Drug 278,500 0.3% Medicare Sequestration 143.000 0.2% Sub Total \$ 3,895,600 4.3% Other 2.947.900 3.3% Total NPR Increase FY21 to FY22 Budget \$ 6,843,500 7.6%



INCOME STATEMENT, BALANCE SHEET CASH FLOW NPR/FPP - SUMMARY OF BUDGET REQUEST


- Requesting Average Rate Increase of 3%
 - 5 Year Average Rate Increase <3.25%
 - Each 1% Rate Increase Yields \$401,300 NPR
 - 3.4% Increase for Hospital Services
 - Recently Completed CDM and Price Comparison Analysis Will Guide Increase Strategy
 - 0% Increase for Provider Services
- NPR Increase Due to Utilization = 1.7%
 - Provider Practices, Operating Room & Physical Therapy
 - Budgeting Up to 10 Telehealth Visits Per Week in Primary Care Practices
 - Volume of Avoidable ED Visits Decreasing

| | | Avoidable | % |
|----------------|------------------|-----------|-----------|
| January - June | ED Visits | Visits | Avoidable |
| FY 2018 | 6,039 | 1,642 | 27.2% |
| FY 2019 | 6,307 | 1,764 | 28.0% |
| FY 2020 | 4,357 | 937 | 21.5% |
| FY 2021 | 4,436 | 775 | 17.5% |

- NPR Increase From New or Expanded Services = 1.6%
 - ENT, Audiology, Pulmonary & Pain Management
 - Reduces NPR going from VT to NH
 - NVRH Becoming Regional Provider for Certain Specialty Services



INCOME STATEMENT, BALANCE SHEET & CASH FLOW CHARGE INCREASE REQUEST TRENDED CHARGE INCREASE %



INCOME STATEMENT, BALANCE SHEET & CASH FLOW NPR/FPP - PAYER ASSUMPTIONS

- No change to commercial payer discounts
- No change to Medicare CAH payment rules
- Assume Medicare Sequestration begins 1/1/22
- No change to Medicaid FFS reimbursement rates
- NVRH plans to participate in all OCV Value-Based Programs except Medicare Risk Program
- Lower Uncompensated Care trend will continue
 - No changes to Uncompensated Care Policies
 - Anticipated economic effect of COVID on UC didn't materialize



INCOME STATEMENT, BALANCE SHEET & CASH FLOW ADJUSTMENTS

- The FY 2022 budget does not include any Provider Transfers
- There were no Accounting Changes adopted in FY 2021 and none anticipated for FY 2022



INCOME STATEMENT, BALANCE SHEET & CASH FLOW OTHER OPERATING & NON-OPERATING REVENUE

| INCOME STATEMENT | 2020 A | 2021 B | 2021 PROJ | 2022 B |
|-----------------------------------|-------------|-------------|-------------|-------------|
| Other Operating Revenues | | | | |
| 340B Retail Pharmacy Programs | \$2,712,187 | \$2,575,000 | \$2,314,633 | \$2,400,000 |
| COVID-19 Stimulus and Other Grant | \$1,788,510 | \$597,400 | \$1,160,140 | \$0 |
| Grant Income | \$117,759 | \$0 | \$0 | \$0 |
| Reference Lab Revenue | \$1,458,431 | \$1,525,000 | \$1,731,307 | \$1,725,000 |
| Meaningful Use | \$0 | \$0 | \$0 | \$0 |
| Other | \$34,000 | \$210,000 | \$339,540 | \$340,100 |
| Other Operating Revenue | \$6,110,887 | \$4,907,400 | \$5,545,620 | \$4,465,100 |
| | | | | |
| Non Operating Revenue | \$2,418,526 | \$0 | \$3,503,586 | \$0 |

- OOR is comprised mostly of 340B and Reference Lab
- FY 2021 Stimulus Grant Fund Revenue may be higher
- Vaccination Clinic is OOR. It operates at breakeven
- Non-Operating Revenue is primarily gains or losses on investments, which NVRH does not budget



INCOME STATEMENT, BALANCE SHEET & CASH FLOW EXPENSES — FY 2021 to FY 2022 BUDGET

Operating Expense Change

FY 2021 Budget to FY 2021 Budget

| Description | | Amount | % | Comments |
|---|----|------------|-------|--|
| Total FY21 Budget Operating Expenses | \$ | 93,488,000 | | |
| Provider Tax Increase | | 825,000 | 0.9% | FY 2020 NPR Projected Too Low |
| New/Expanded Programs and Services | | 1,300,000 | 1.4% | Pulmonology, ENT, Pain Management |
| Unbudgeted COVID Testing Expenses | | 369,700 | 0.4% | Ongoing Testing Anticipated But At Reduced Level |
| OR Supply Costs (Implants Mostly) | | 550,000 | 0.6% | Volume Continues to Increase |
| Pharmacy Drug (One Drug) | | 278,500 | 0.3% | Annual Cost Now \$1.1 Million |
| Locum Expense Variance | | (325,000) | -0.3% | Anticipated Reduction Based on Staffing Assumptions |
| Provider & Employee Recruitment | | 375,000 | 0.4% | Recruitment to Fill Current and Anticipated Vacancies |
| FY21 Employee Increase Implemented Early | | 275,000 | 0.3% | Carry Forward to FY 2022 |
| ncrease Depreciation Expense | | 348,800 | 0.4% | Returning to Normal Capital Expenditure Plan |
| nflation | | 550,000 | 0.6% | Non Salary Inflation Average of XX% Assumed |
| Salary Increase | | 1,000,000 | 1.1% | Includes Market Adjustments |
| FTE Increase | | 775,000 | 0.8% | Screeners, Patient Observers, Analytics, Staff Education |
| Volume Related Expenses | | 320,000 | 0.3% | Incremental Expenses Related Volume Increase |
| Cost Savings/ Expenses Lower Than Budget | _ | (361,100) | -0.4% | 340B and Supply Chain Savings Budgeted at \$200,000 |
| Total FY2021 Projected Operating Expenses | \$ | 99,768,900 | 6.7% | |



INCOME STATEMENT, BALANCE SHEET & CASH FLOW OPERATING MARGIN-FY 2018 to FY 2022 TRENDED





OPERATING MARGIN/TOTAL MARGIN

- Five-Year Average Operating Margin is 1.8%
- Minimum of 2% Operating Margin Required in FY 2021 and Beyond to Support Emergency Department/West Wing Project – Estimated Cost \$22 Million
- Total Operating Margin = Operating Margin +/- Gains or Losses on Investments (Not Budgeted)



INCOME STATEMENT, BALANCE SHEET & CASH FLOW BALANCE SHEET

| BALANCE SHEET | 2019 A | 2020 A | 2021 P | 2022 B |
|--------------------------------------|---------------------|--------------|--------------|--------------|
| Cash & Investr | nents \$5,802,95 | \$28,733,062 | \$26,505,258 | \$13,670,959 |
| Net Patient Accounts Recei | vable \$9,251,739 | \$8,715,262 | \$9,718,000 | \$10,602,000 |
| Due From Third P | arties \$6 | \$0 | \$0 | \$0 |
| Risk Reserve Recei | vable \$(| \$0 | \$0 | \$0 |
| Other Current A | ssets \$4,096,24 | \$3,521,751 | \$3,492,654 | \$3,250,000 |
| Current Assets | \$19,150,93 | \$40,970,075 | \$39,715,912 | \$27,522,959 |
| Board Designated A | ssets \$18,880,55 | \$20,793,491 | \$24,028,949 | \$24,028,949 |
| Net, Property, Plant And Equip | ment \$23,016,18 | \$22,455,672 | \$23,754,017 | \$26,024,017 |
| Other Long-Term A | ssets \$7,622,39 | \$7,442,663 | \$7,137,798 | \$6,278,864 |
| Assets | \$68,670,063 | \$91,661,901 | \$94,636,676 | \$83,854,789 |
| Accounts Pa | yable \$2,633,14 | \$4,474,753 | \$3,311,675 | \$3,600,000 |
| Current Liabilities COV | ID-19 \$(| \$6,263,821 | \$10,809,222 | \$0 |
| Salaries, Wages And Payroll Taxes Pa | yable \$5,757,70 | \$5,194,885 | \$6,834,307 | \$6,026,807 |
| Other Third Party Settler | nents \$1,668,35 | \$3,063,418 | \$1,878,040 | \$1,055,540 |
| ACO Risk Re | serve \$6 | \$0 | \$377,500 | \$1,019,375 |
| Other Current Liab | ilities \$1,133,00 | \$1,432,417 | \$4,158,941 | \$2,945,506 |
| Current Liabilities | \$11,192,203 | \$20,429,294 | \$27,369,685 | \$14,647,228 |
| Long Term Liabilities COV | ID-19 \$(| \$10,778,846 | \$0 | \$0 |
| Long Term Liab | ilities \$10,385,29 | \$10,046,480 | \$7,703,002 | \$6,893,002 |
| Other Noncurrent Liab | ilities \$4,737,45 | \$4,463,755 | \$8,407,919 | \$9,094,489 |
| Long Term Liabilities | \$15,122,74 | \$25,289,081 | \$16,110,921 | \$15,987,491 |
| Total Liabilities | \$26,314,94 | \$45,718,375 | \$43,480,606 | \$30,634,719 |
| Net A | ssets \$40,765,49 | \$42,343,782 | \$45,669,228 | \$51,155,032 |
| YTD Change In Net A | ssets \$1,589,62 | \$3,599,744 | \$5,486,842 | \$2,065,038 |
| Fund Balance | \$42,355,119 | \$45,943,526 | \$51,156,070 | \$53,220,070 |
| | | | | |
| Liabilities and Equities | \$68,670,063 | \$91,661,901 | \$94,636,676 | \$83,854,789 |
| | | | | |
| Balance Sheet Metrics | | | | |
| Days Cash on | Hand 107. | 206.6 | 196.0 | 143.0 |
| Debt Service Coverage Ratio | o to 1 5.: | 1 4.5 | 4.8 | 5.4 |
| Long Term Debt to Capitaliz | ation 0.3 | 0.3 | 0.1 | 0.1 |
| Days Pa | yable 48. | 7 85.2 | 106.1 | 55.5 |
| Days Recei | vable 39.9 | 9 40.2 | 41.4 | 43.6 |



INCOME STATEMENT, BALANCE SHEET & CASH FLOW BALANCE SHEET

- Increasing cash balance for investment in ED/West Wing project and support subsequent debt service
 - Days Cash on Hand increasing from 107 to 143 (FY19-FY22)
- Capital structure ratios indicate capacity to add long term debt for ED/West Wing project
 - Debt Service Coverage Ratio = 5.4
 - Long term debt to Capitalization Ratio = .1

INCOME STATEMENT, BALANCE SHEET & CASH FLOW CASH FLOW

| Cash Flow | Amount |
|--|--------------|
| Cash From Operations | |
| Excess Revenue Over Expense | 2,065,038 |
| Depreciation/Amortization | 3,508,500 |
| Repayment Medicare Advance Payment | (10,809,222) |
| Increase Patient A/R | (884,000) |
| Other Changes | (1,670,581) |
| Total Cash From Operations | (7,790,265) |
| Cash From Investing Activity | |
| Capital Spending | |
| Change in Accum Depr Less Depreciation | (118,500 |
| Change in Capital Assets | (5,660,000 |
| Total From Investing Activity | (5,778,500 |
| Other LT Assets & Escrowed Bonds & Other | 1,545,504 |
| Total Other LT Assets & Escrowed Bonds | 1,545,504 |
| Financing Activity | |
| Debt | |
| Bonds & Mortgages | (810,000 |
| Total Financing Activity | (810,000 |
| Other Changes | |
| Change in Fund Balance Less Net Income | (1,038 |
| Total | (1,038 |
| Total Increase (Decrease) in Cash | (12,834,299 |
| | |
| Beginning Cash | 26,505,257 |
| Net Increase/(Decrease) in Cash | (12,834,299 |
| Ending Cash | 13,670,958 |



RISKS AND OPPORTUNITIES RISKS


Risks That Could Negatively Affect FY 2022 Budget Include:

- Tightening labor market impacting recruitment/retention at all levels
- Effect of staffing new DHMC Tower on already tight labor market
- Inability to locate travelers to fill vacant positions due to high demand, short supply
- Mandated vaccinations could negatively influence recruitment/retention
- Inflationary pressures
 - Labor costs
 - Supply chain
 - Equipment and construction
- Chronic strain on mental health system
- Inadequate system capacity for patient transfers
 - Availability of tertiary beds
 - Availability of mental health beds
 - Availability of post-acute beds



RISKS AND OPPORTUNITIES RISKS


Impact of Inadequate Supply of Mental Health Beds





RISKS AND OPPORTUNITIES RISKS

Impact of Inadequate Supply of Mental Health Beds (Cont'd)





RISKS AND OPPORTUNITIES RISKS

- COVID-19 Resurgence
 - Schools returning to remote learning will impact staffing
 - Potential supply chain disruption and availability of PPE
- Further erosion of 340B revenue due to withdrawal of additional drug manufacturers
- Possibility of local Designated Agency losing its designation
- Unfavorable OCV Value-Based Program results



RISKS AND OPPORTUNITIES OPPORTUNITIES

Opportunities to Positively Affect FY 2022 Budget and/or Reduce Risks Include:

- Use VT status as "safe" state to support recruitment efforts
- Maximize Tele-Psychiatry Program to support continuity of care throughout the enterprise
- Continue use of Telehealth Services to improve access to care
- Continued use of 340B Program to reduce drug costs
- Continued work with providers to offset lost 340B revenue due to drug manufacturers withdrawal from program
- Favorable OCV Value-Based Program results

RISKS AND OPPORTUNITIES OPPORTUNITIES

- Leverage OCV data and analytics to further improve care coordination
- Improve operational efficiencies though cross-departmental collaboration
- Introduce new patient-centered technology to optimize patient services and health care delivery
- Develop an exemplary nursing education program to support recruitment and retention efforts

VALUE-BASED PARTICIPATION

- NVRH Will Participate in All Value-Based OCV Programs Except Medicare
 - Total risk budgeted is \$812,500
 - Medicare down-side risk Too High for CAHs

Value-Based Care Participation

Complete the following table if the hospital is participating in one or more of value-based care programs. If the hospital is not participating in value-based care programs, please indicate in the narrative.

| Value-Based Care Program | Participating in Program in Calendar Year (CY) 2022? (Yes/No) | _ | Budgeted Amount of FPP (monthly average for CY 2022) | Budgeted Maximum Upside/Downside Risk for CY 2022 |
|-------------------------------|--|-------|---|--|
| Medicaid | Υ | 7,878 | 752,300 | (812,500) |
| Medicare | TBD | | | |
| Commercial (not Self-Insured) | Υ | 4,512 | 0 | |
| Self-Insured | | | | |
| TOTAL | | | | |



CAPITAL INVESTMENT PLANS

- Routine Capital Spending = \$2.6 Million
- Phase A of ED/West Wing Project = \$2.8 Million
 - Plan to fast track Mental Health Support Waiting Area portion of larger project
- Phase B of ED/West Wing CON Preparation = \$.3 million
- CON application for ED West Wing Project will be filed in Fall,
 2021
 - \$19 Million in FY 2021 Dollars
 - \$22 Million in FY 2023 Dollars (estimated start date)
- FY 2022-2026
 - Upgrade Meditech EMR =\$2.5 Million
- Committee reviews capital plan monthly



IMPACT OF COVID-19

- Implement Change Management Models:
 - Stood up new programs quickly and efficiently
 - Monoclonal Antibody Infusion Center
- Operational efficiencies that were maintained Post-COVID:
 - Remote Meetings
 - Telehealth Visits
- Work Remotely Pilot project to make permanent in progress
- Increased NVRH's negative pressure room capacity
 - ED, Med/Surg, ICU and Medical Practices (4)
- Renewed NVRH's commitment to focus on staff well-being
 - Lumonos Wellbeing Program for providers and staff
- Drive Through Services are a huge success
 - COVID Testing, Flu and COVID Vaccination



IMPACT OF COVID ONGOING COVID-19 CHALLENGES

- High Acuity Patients (due to delayed care)
 - Put increased strain on already-stretched staff
 - Require more system resource to care For
 - Resulting in longer wait times (especially in Specialties)
- COVID Protocol Requirements Add Complexity
 - Makes visit and process longer

